Glossary
A | B | C | E | F | G | H | I | L | M | O | P | Q | R | S | T | W
A
- Adenovirus
- Certain type of virus. Most infections with adenovirus result in infections of the upper res-piratory tract
- Affinity
- Binding strength between binding partners, e. g. antibody/antigen
- Amyloid-beta
- Target molecule in Alzheimer’s disease therapy; main constituent of amyloid plaques in the brains of Alzheimer’s disease patients
- Antigen
- Foreign substance stimulating antibody production; binding partner of antibody
- Antibody
- Proteins of the immune system that recognize antigens, thereby triggering an immune response
- Antibody library
- A collection of genes that encode corresponding human antibodies
- Autoimmune disease
- Disease caused by an immune response by the body against one of its own tissues, cells or molecules
B
- Biomarker
- Substance used as an indicator of a biological state. Can be objectively measured and evaluated as an indicator of pharmacological responses to a therapeutic intervention
- Biosimilars
- Term used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiry
C
- Cash flow
- Key performance indicator in the cash flow statement used to assess the financial and earning capacity
- CD20
- Therapeutic target for the treatment of B-cell lymphomas and leukemias
- CDO
- Chief Development Officer; executive function within a company
- Clinical trial
- Clinical trials allow safety and efficacy data to be collected for new drugs or devices. Depending on the type of product and the stage of its development, investigators enroll healthy volunteers and/or patients into small pilot studies initially, followed by larger- scale studies in patients
- CMO
- Contract manufacturing organization; term used in the pharmaceutical industry for a firm whose expertise lies in manufacturing the biologics for market
- COGS
- Cost of goods sold; costs for antibody material produced by the AbD segment
- Corporate Citizenship
- Form of corporate self-regulation integrated into a business model, which means adhering to laws and complying with certain standards
- Corporate Governance
- System of relations between the shareholders, Board of Directors and management of a company
- Crohn’s disease
- An autoimmune disease caused by the immune system attacking the gastrointestinal tract and producing inflammation
- Cytokine
- A protein that acts as a chemical messenger to stimulate cell migration
E
- EMEA
- European Medicines Agency
- Expression
- Conversion of genetic information in a corresponding protein
F
- FDA
- Food and Drug Administration; US federal agency for the supervision of food and drugs
G
- Gene
- Part of DNA encoding a defined structure (e. g. a protein) or a function
- GM-CSF
- Granulocyte-macrophage colony-stimulating factor; underlying target molecule of MOR103 program
- GMP
- Good manufacturing practice; term for the control and management of manufacturing and quality control testing of pharmaceutical products and medical devices
- Goodwill
- An intangible asset that reflects the value of a company’s name and reputation, its customer relations, and other factors influencing its standing and competitiveness
- GRS study
- Annual German biotechnology industry remuneration study
H
- HGB
- German Commercial Code
- HuCAL
- Human Combinatorial Antibody Library; proprietary antibody library enabling rapid generation of specific human antibodies for all applications
- Human
- Of human origin
I
- IFRS
- International Financial Reporting Standards; future EU-wide standards produced by the IASB
- IgG
- Immunoglobulin G; class of antibody, most abundant immunoglobulin, constituting 75 % of serum immunoglobulins in humans
- Immunization
- Generation of antibodies by administering antigen
- IND
- Investigational new drug; application, by which a company files a request with FDA for permission to expose its experimental drug to patients or healthy volunteers in clinical trials
- in-vitro
- in a test tube
- in-vivo
- in a living organism
L
- Life Sciences
- All branches of science that study all organisms, especially living ones
M
- Market capitalization
- Value of a company’s outstanding shares, as measured by shares times current price
- M&A
- Mergers and acquisitions
- Milestone
- Predefined events relating to the development of the substance into a drug
- Monoclonal antibody
- Homogenous antibody originating from a single clone, produced by hybridoma cell
- Multiple myeloma
- Type of cancer that develops in a subset of white blood cells called plasma cells formed in the bone marrow
- Multiple sclerosis
- Disease of the central nervous system characterized by the destruction of nerve fibers
O
- Osteoarthritis
- A group of diseases and mechanical abnormalities entailing degradation of joints and bones
- Osteoporosis
- A bone disease that leads to an increased risk of fracture
P
- Phage
- Abbreviation for bacteriophage, a virus that infects bacteria
- Phage-display technology
- Screening technology; presentation of peptides/proteins on surface of phages
- Pharmacokinetics
- Determination of the fate of substances administered externally to a living organism
- Plaque psoriasis
- Most common form of psoriasis, a chronic, non-contagious autoimmune disease which affects the skin and joints
- PML
- Progressive multifocal leukoencephalopathy; rare and potentially fatal viral disease that is characterized by progressive damage or inflammation of the white matter of the brain
- Preclinic
- Preclinical stage of drug development; tests in animal models as well as in laboratory assays
- Protein
- Polymer consisting of amino acids, e. g. antibodies and enzymes
Q
- QA
- Quality assurance; a set of activities intended to ensure that products (goods and/or services) satisfy customer requirements in a systematic, reliable fashion
R
- RapMAT
- Maturation process; proprietary technology of MorphoSys
- R & D
- Research and development
- Reagent
- A substance used in research and diagnostic applications
- Recombinant
- Formed by (re)combination of parts of one or different starting DNA molecules
- Rheumatoid arthritis
- Inflammatory disease of the joints; abbreviation: RA
- Royalties
- Percentage share of ownership of the revenue generated by drug products
S
- S, G & A
- Sales, general and administrative
- Specificity
- Property of antibodies, for example, to discriminate between different, but similar, antigens
T
- Target
- Target molecule for therapeutic intervention, e. g. on surface of diseased cell
- TecDAX
- Index of the 30 largest technology companies listed on the Frankfurt Stock Exchange
- TNF
- Tumor necrosis factor; important cytokine involved in systemic inflammation in RA patients
W
- WACC
- Weighted average cost of capital; the rate that a company is expected to pay to finance its assets
